NIH Grants

Mobile Health (mHealth): Technology and Outcomes in Low and Middle Income Countries is a grant from the Fogarty International Center at NIH that funds research on mobile health technologies and their outcomes in low and middle income countries. Administered as an R21/R33 Phased Innovation Award, this funding opportunity supports studies that leverage mHealth tools to address health challenges in resource-limited settings. Participating NIH components include FIC, NEI, NIBIB, NICHD, NIDCD, NIMH, and NCI. Applications must align with the mission of the participating institutes. The program accommodates clinical trial optional designs. Award amounts vary by application and institute. The deadline for the most recent cycle was March 20, 2026.

Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD) / National Institutes of Health (NIH). This notice solicits grant applications seeking to improve women's health across the lifespan within the scope of NIDCD's mission.

LAUNCH Program is sponsored by National Institutes of Health (NIH). The LAUNCH program supports the training of future global health researchers by providing early career researchers in the U.S. an opportunity for immersion in the wide-ranging health conditions and challenges experienced in international low-resource settings and to partner with local health researchers.

NLM Information Resource Grants to Reduce Health Disparities and Promote Health for All (G08 Clinical Trial Not Allowed) is sponsored by National Library of Medicine (NIH). This funding opportunity supports the development of information resources and services that provide accurate health information to populations experiencing health disparities and their providers, to improve health literacy, decision-making, and reduce disparities.

Notice of Special Interest (NOSI): Administrative Supplements for Research on Women's Health in Low- and Middle-Income Countries (LMICs) is sponsored by Office of Research on Women's Health (ORWH), National Institutes of Health (NIH). This NOSI announces the availability of administrative supplements to existing NIH grants to support research on women's health in LMICs. This could include research on women's health cancers within the scope of an existing grant.

Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (RFA-EB-26-003) is sponsored by National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB). This Notice of Funding Opportunity (NOFO) solicits applications to enhance bioengineering and imaging research capacity, technology innovation, education and research training, and opportunities for scientific growth at Historically Black College and Universities (HBCUs).

Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required) (PAR-25-342) is sponsored by National Institutes of Health (NIH). This funding opportunity supports innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos. While the title emphasizes NCDs, the broader theme of improving health outcomes and addressing disparities in Latin America can be relevant for global health and infectious disease research, especially where co-infections or social determinants of health play a role.

Novel Experiential Technologies Assisting Individual Learning Hubs (NExT AI Hubs) is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) - NIH. This initiative seeks to advance NICHD's mission through a Centers program that will carry out research on understudied, highly innovative, and high-risk research topics related to the impact of Artificial Intelligence (AI) technologies on developmental outcomes in children at r…

Research Grants in Clinical Informatics (R01 Clinical Trial Optional) is sponsored by U.S. Department of Health and Human Services, National Institutes of Health (NIH). This NIH funding opportunity supports innovative clinical informatics research to transform health data into actionable knowledge. While broad, it can include projects leveraging AI for data analysis and integration to advance biomedical research.

Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional) is sponsored by U.S. Department of Health and Human Services; National Library of Medicine; National Institutes of Health (NIH). This program supports innovative, scalable bioinformatics research with broad biomedical impact. This can include AI applications within bioinformatics, translational bioinformatics, and computational biology.

Research Council of Finland (RCF) – National Institutes of Health (NIH) Partnership Program (PA-26-085) is sponsored by NIH Fogarty International Center. This program funds collaborative health research projects between U.S. and Finnish universities. While not explicitly focused on traditional medicine or complementary health, research in global health could be part of the collaborative projects.

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity invites investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically GLP-1 or dual GLP-1/GIP-1 receptor agonists, impact cancer risk. The focus includes reported effects on thyroid, prostate, and other cancer risks. The NOFO also aims to attract scientists from other fields to study incretin mimetic effects on cancer biology.

Institutional Mentored Career Development Award (K12) is sponsored by National Institutes of Health (NIH). This program supports institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers and to facilitate their transition to more advanced support mechanisms, such as K08 and K23.

Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD) / NIH. This funding opportunity supports early-stage dissemination and implementation (D&I) research projects in NIDCD mission areas, including hearing and balance. It aims to support projects that will set a foundation for a high-quality, D&I focused R01.

NCATS program (PAR-25-157) supporting development of innovative technologies for translational science including AI/ML-driven drug discovery, high-throughput screening automation, computational target identification, and novel assay platforms. Funds exploratory research that creates new tools, methods, and technologies to overcome specific translational bottlenecks in the drug development pipeline. Part of NCATS' broader mission that has enabled over 45 promising new drugs to move into clinical trials through partnerships with academia, industry, and patient advocacy groups. NCATS maintains a pharmaceutical collection of nearly every human-approved drug and automated solutions for rapid drug repurposing screening including for emerging infectious diseases.

Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) is sponsored by National Institutes of Health (NIH). The NIH offers various funding opportunities for behavioral and social sciences research. While this specific R21 announcement title doesn't explicitly mention 'consumer behavior marketing science,' R21 grants support exploratory/developmental research, and consumer behavior aspects could be relevant within broader translational science, especially related to health behaviors. Researchers are encouraged to filter announcements by agency, topic, eligibility, or deadline on Grants.gov.

New Generation of Glucose Control Technologies Incorporating AI/ML is a funding announcement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at NIH that will solicit applications for research to improve open- and closed-loop diabetes control systems for Type 1 diabetes. Research priorities include innovations in analyte sensing, novel hormone formulation and delivery, AI and machine learning-driven algorithms, and digital twin modeling to enhance glycemic control and quality of life. Awards will use the R01 research project grant activity code. Applications are not yet being solicited but the notice was issued to allow potential applicants time to develop meaningful collaborations. Eligible applicants include universities, nonprofits, Tribal governments, for-profit organizations, and federal agencies.

Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3, Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) (NCI also participating). This funding opportunity supports the development of biomarkers or clinical outcomes from digital health technology for remote monitoring in clinical trials.

Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development is sponsored by National Institutes of Health (NIH) / National Cancer Institute (NCI). This funding opportunity focuses on digital health approaches that can significantly advance the assessment, monitoring, and understanding of cancer risk factors and determinants and increase participant reach and engagement in cancer research.

Research on the Impact of Technology and Digital Media on Children and Adolescents (Forecasted) is sponsored by National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). NICHD intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on the impact of technology and digital media on children and adolescents.

BRAIN Initiative: Production and distribution facilities for brain cell type-specific access reagents (U24 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. This BRAIN Initiative Notice of Funding Opportunity (NOFO) aims to support the establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific …

Instrumentation Grant Program for Resource-Limited Institutions (RLI-S10) is a grant from the National Institutes of Health (NIH), administered by the National Institute of General Medical Sciences (NIGMS), that supports acquisition of modern scientific instruments for research and education at resource-limited institutions. Awards range from ,000 to ,000. Instruments may support basic, translational, clinical, or biomedically related behavioral science research and may also be used in upper-level and graduate courses. This program targets institutions with limited existing research infrastructure, helping to enhance their biomedical research and education capacity. The deadline for the current cycle is July 2, 2026.

Native American Research Centers for Health (NARCH) is sponsored by Indian Health Service, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS). This program offers grants for new or continued Native American Research Centers for Health, which support health-related research, research career enhancement, and research infrastructure enhancement activities to meet the health needs of American Indian/Alaska Native (AI/AN) communities.

Native American Research Centers for Health (NARCH) is sponsored by Indian Health Service (IHS), National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS). This program offers grants for new or continued Native American Research Centers for Health, which support health-related research, research career enhancement, and research infrastructure enhancement activities to meet the health needs of American Indian/Alaska Native (AI/AN) communities nationwide.

Tuberculosis Research Advancement Centers (TRACs) (P30 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) - NIH. The TRACs program aims to develop the next generation of TB researchers and catalyze multidisciplinary and innovative TB science by providing expertise and resources to facilitate basic and clinical TB research.

NINDS Research Education Programs for Residents and Fellows in Neurology and Neurosurgery (R25) is sponsored by NIH National Institute of Neurological Disorders and Stroke (NINDS). This program supports institutions to develop and implement research education and training programs for clinical residents and fellows in neurological sciences, including neurosurgery, to foster careers as physician-scientists.

NIH HEAL Initiative Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). NIH HEAL Initiative Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is a grant from the National Institutes of Health that funds investigators developing small molecule …

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This program supports small molecule drug discovery and development for disorders of the nervous system, which can include AD/ADRD.

Notice of NCATS Participation in Notice of Funding Opportunity (NOFO) PA-25-304 NIH Exploratory/Developmental Research Project Grant (Parent R21 Clini... is sponsored by National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH). This notice indicates NCATS's participation in the NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) program, highlighting areas of interest for translational science research within this mechanism.

HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) HEAL Initiative. This funding opportunity supports early-stage discovery research for new pain targets within the understudied druggable proteome as part of the NIH HEAL (Helping to End Addiction Long-term) Initiative, which aims to address the opioid overdose crisis and improve pain management.

Global Collaborative Research Training on Non-Communicable Diseases and Disorders Across the Lifespan is sponsored by National Institutes of Health (NIH) - Fogarty International Center. This initiative supports rigorous institutional research training programs for low- and middle-income country (LMIC) scientists that enhance collaborative NIH research with U. S. scientists on specific noncommunicable diseases (NCDs), disorders, and health conditions.

Native Collective Research Effort to Enhance Wellness (N CREW) Program: Addressing Overdose, Substance Use, Mental Health, and Pain is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences, National Institute on Drug Abuse. This program provides funding for community-led research to enhance culturally grounded, strengths-based, effective, and sustainable interventions addressing overdose, substance use, mental health, and pain in Native communities.

NIH Accelerator Program is sponsored by National Institutes of Health (NIH) (Collaborative effort with Prisma Health Education and Research Institute, Clemson University, University of South Carolina School of Medicine Greenville, and the Addiction Medicine Center). This is an intensive mentoring program for faculty investigators seeking NIH funding. The program aims to strategically position early-career investigators to develop complete and competitive NIH grant applications.

The Global Infectious Disease Research Training Program (D43) is a grant from the Fogarty International Center and NIAID at the NIH that funds collaborative research training programs to strengthen infectious disease research capacity in low- and middle-income countries (LMICs). Priority areas include antimicrobial resistance (AMR) and infectious disease surveillance, particularly at African institutions. Applications must be submitted jointly by a U.S. institution of higher education and an equivalent non-U.S. institution in an LMIC. Awards range from $250,000 to $1,500,000 per year. The application deadline is August 6, 2026. This is an ongoing funding opportunity announcement with multiple application receipt dates.

Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) is sponsored by NIH Fogarty International Center. This program supports institutions in low- and middle-income countries to strengthen their research administration capacity for global health research. It encourages collaborative applications from U. S.

Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) is sponsored by U.S. Department of Health and Human Services, National Institutes of Health (NIH). This grant supports collaborative research on health disparities and NCDs in Latin America and U. S. Hispanic/Latino populations, emphasizing cross-national partnerships.

Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional) is sponsored by National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH). This grant supports a coordinating center for the Research Centers in Minority Institutions (RCMI) program, which aims to enhance the research capacity of institutions that serve underrepresented minority populations.

NIH Director's New Innovator Award (DP2) is sponsored by National Institutes of Health (NIH) Common Fund. The NIH Director's New Innovator Award, part of the High-Risk, High-Reward Research program, supports early-career investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the NIH mission. This award explicitly does not require preliminary data and encourages risky, transformative ideas. Research areas relevant to AI are included.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS)/NIH. This program supports small molecule drug discovery and development for disorders of the nervous system, including neurodegenerative diseases. It is part of the NIH Blueprint for Neuroscience Research.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by NIH National Institute of Neurological Disorders and Stroke (NINDS). This program supports the discovery and development of small molecule drugs for disorders of the nervous system, which can include AD/ADRD. It provides a comprehensive pipeline for therapeutic development from target validation to clinical trials.

NIH Director's Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional) RFA-RM-27-003 is sponsored by National Institutes of Health (NIH). This award supports exceptionally innovative and unconventional research projects that have the potential to create new paradigms or break existing ones. This can include research leading to new diagnostic approaches in medicine.

NIH Director's Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional) (RFA-RM-27-003) is sponsored by National Institutes of Health (NIH) Common Fund. This award supports individual scientists or groups proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new paradigms in infectious biology and beyond.

NIH Small Business Technology Transfer Grant: Parent STTR R41/R42, Clinical Trial Optional (PA-27-102) is sponsored by National Institutes of Health (NIH). This NIH STTR grant supports U.S. small businesses conducting biomedical or life-sciences research and development in formal partnership with nonprofit research institutions. The program aims to help small companies develop technologies and products that support NIH's mission to improve health, extend life, and reduce illness and disability.

Small Business Innovation Research Program (SBIR) is sponsored by Various Federal Agencies (e.g., NIH, USDA, DOE, DOD). The SBIR program awards grants to U. S. -based small businesses for federal research or research and development (R&D) that can be commercialized. One of its goals is to encourage entrepreneurship among women and economically disadvantaged communities.

NIH Small Business Technology Transfer Grant Parent STTR [R41/R42] Clinical Trial Optional is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This parent announcement supports small business technology transfer (STTR) grants, fostering technology transfer through cooperative R&D between small businesses and non-profit research institutions. Applications are accepted three times a year.

Small Business Innovation Research (SBIR) Program and the Small Business Technology Transfer (STTR) Program is sponsored by National Institutes of Health (NIH). NIH's SBIR and STTR programs support research and development in small businesses to drive technological innovation and translate scientific discoveries into health improvements. In FY25, NIH committed to boosting investments in small business innovations focused on women's health research. While not exclusively for agriculture, the focus on innovation and women's health may present opportunities for agricultural technologies that impact women's health, such as those related to food production and rural health.

NIH SBIR/STTR Parent SBIR (R43/R44) Clinical Trial Not Allowed (PA-24-245) is sponsored by National Institutes of Health (NIH). The NIH SBIR program supports small businesses developing innovative technologies that address health-related challenges through Phase I and Phase II funding, focusing on establishing technical feasibility, research and development, and advancing toward commercialization.

NIH SBIR/STTR Parent STTR (R41/R42) Clinical Trial Not Allowed (PA-24-247) is sponsored by National Institutes of Health (NIH). The NIH STTR program supports small businesses in formal cooperative R&D with a non-profit research institution to develop innovative health-related technologies, without a clinical trial component, from early feasibility through later-stage commercialization.

Small Business Innovation Research (SBIR) Program (Parent SBIR [R43/R44]) is sponsored by National Institutes of Health (NIH), Department of Health and Human Services (HHS), Centers for Disease Control (CDC), Food and Drug Administration (FDA). This omnibus solicitation encourages small businesses to submit investigator-initiated SBIR grant applications for research and development across a broad spectrum of health-related topics with commercialization potential.

Small Business Technology Transfer (STTR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA STTR program encourages small businesses to collaborate formally with research institutions to develop and commercialize innovative treatments or technologies to help people enjoy healthier lives as they age, including solutions for Alzheimer's disease and related dementias. This program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.

Small Business Innovation Research (SBIR) Grants (R43 and R44) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This program supports research and development of aging- and health-focused products and services by small business concerns that may ultimately lead to commercialization. This includes innovative tools, technologies, and interventions to prevent, diagnose, treat, monitor, or slow progression of AD/ADRD, cognitive decline, age-related sleep disorders, and delirium. Also includes technologies and interventions that promote healthy aging, support aging in place of choice, improve care delivery, or reduce caregiving burden, such as assistive devices, robotics, sensors, digital health products, and technologies to enhance care.

PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) (Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI) of the National Institutes of Health (NIH). This omnibus solicitation supports small business technology transfer research across a broad spectrum of topic areas related to the NCI's mission, without requiring a clinical trial. It aims to facilitate cooperative R&D between small business concerns and U.

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This parent announcement supports small businesses in developing innovative health-related technologies, from early feasibility through later-stage commercialization. Applications are accepted three times a year.

Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health, NOT-EB-23-005 is sponsored by National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This Notice of Special Interest (NOSI) seeks to advance maternal health research through small business innovation, focusing on projects for detecting, predicting, and/or monitoring conditions or disorders during pregnancy and/or the post-partum period that contribute to maternal morbidity and mortality. This includes clinical trials. The initiative is part of the 'Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)' initiative. Small businesses are encouraged to develop technologies, remote monitoring systems, clinical analytics platforms, and healthcare delivery solutions. While not explicitly mentioning GIS, the focus on 'clinical analytics platforms' and 'maternal risk prediction' suggests that GIS secondary data analysis could be a relevant tool in developing such innovative solutions.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (NIH) is sponsored by National Institutes of Health (NIH). The NIH SBIR/STTR programs are congressionally-mandated set-aside programs that encourage research and development by small businesses, with the goal of commercialization and public benefit. They support innovative ideas at different stages of development, including applied bench research, translational research, and early-stage clinical trials, particularly in areas of neuroscience and mental health relevant to NIH's mission.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (Omnibus Solicitations) is sponsored by National Institutes of Health (NIH). The NIH SBIR/STTR programs provide non-dilutive funding for groundbreaking research and development projects that address critical needs in healthcare and biomedical science. These omnibus solicitations welcome investigator-initiated ideas across a broad range of topics relevant to NIH's mission areas. Applications are accepted three times per year.

Small Business Technology Transfer (STTR) Program is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The STTR program, similar to SBIR, supports small businesses collaborating with research institutions on scientific research and development projects with commercial potential. This includes projects focused on women's health research, aiming to bridge the gap between basic science and commercialization.

Small Business Innovation Research (SBIR) Program Phase I is sponsored by National Institutes of Health (NIH) National Institute on Aging (NIA). This program supports small businesses in developing technologies for aging-related health issues, including AI applications in medical procedures and solutions addressing Alzheimer's disease (AD) and AD-related dementias (ADRD) treatment and care. It aims to support healthy aging and aging in place, and develop interventions for aging-related diseases.

Small Business Technology Transfer (STTR) Program (Parent STTR [R41/R42]) is sponsored by National Institutes of Health (NIH), Department of Health and Human Services (HHS), Centers for Disease Control (CDC). This omnibus solicitation supports cooperative research and development between small businesses and non-profit research institutions to advance early-stage biomedical commercialization. It is designed to foster technology transfer.

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control (CDC), and Food and Drug Administration (FDA). This program provides non-dilutive funding for early-stage research and development in biomedical and behavioral science, aligning with the missions of NIH, CDC, and FDA.

Small Business Transition Grant for New Entrepreneurs (SBIR) — R43 Phase I is a grant from the National Institutes of Health (NIH) that funds early-stage scientific innovation by small businesses aiming to bring biomedical breakthroughs to the commercial marketplace. The Phase I award supports feasibility research, evaluating technical merit and commercial potential of proposed innovations. Eligible applicants are U.S. small business concerns, particularly new entrepreneurs, applying under PAR-24-131. Awards cover up to approximately $306,872 in total costs for Phase I. The most recent deadline is September 5, 2026.

Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This program provides additional funding for small businesses that have successfully completed Phase II SBIR projects and require extraordinary time and effort in the R&D phase to reach the marketplace. It focuses on biomedical technologies with public health impact.

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA). This program supports small businesses in innovative research with the potential for commercialization, particularly in health-related technologies.

Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This program funds small businesses to conduct research and development with commercial potential in health-related technologies. It supports early feasibility through later-stage commercialization.

Small Business Innovation Research (SBIR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA SBIR program funds small businesses to develop and validate technologies that enhance the health and well-being of older adults, with high interest in technologies addressing unmet needs, improving care delivery, or reducing caregiver burden. This includes AI/ML methods for early detection and monitoring, assistive devices, robotics, sensors, and digital health products.

PHS 2024 Omnibus Solicitation of the NIH and CDC for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). The NIH STTR program supports small businesses that partner with nonprofit research institutions (e. g. , universities) to engage in research and development activities that have strong potential for commercialization.

NIA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA SBIR/STTR programs support small businesses in developing technologies for aging-related health issues, including AI-driven drug discovery tools and assistive technologies for older adults aging in place. These programs aim to help small businesses develop effective treatments and interventions for healthy aging.

Small Business Innovation Research Grants (SBIR R43, R44) - Hazardous Substances Remediation and Detection Program is sponsored by National Institute of Environmental Health Sciences (NIEHS) / NIH. Fosters the commercialization of novel, cost-competitive technologies, products, and devices for remediation and detection of hazardous substances in the environment. Specifically interested in proposals applying new engineering, materials science, and biotechnology approaches.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (Omnibus Solicitations) is sponsored by National Institutes of Health (NIH) Office of Research on Women's Health (ORWH). The NIH SBIR and STTR programs are committed to increasing investments in small businesses engaged in research and development on women's health.

NIA Small Business Programs (SBIR & STTR) is sponsored by National Institute on Aging - NIH. The NIA Small Business Programs manage the largest source of early-stage funding for aging-related research and development (R&D). They provide grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to develop innovative technologies that enhance the health and well-being of older adults, including digital health and sensing technologies that address factors impacting the aging population, Alzheimer's disease, and related dementias. This includes technologies that promote aging in place and reduce caregiving burden.

Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This funding opportunity invites applications for innovative research on the causal factors of human behaviors and the direct or downstream impacts of those behaviors on overall health and oral health among people with chronic conditions.

Small Business Technology Transfer (STTR) Program (NIH Omnibus Solicitation) is sponsored by National Institutes of Health (NIH). The NIH STTR program expands funding opportunities in the federal innovation research and development arena by requiring formal cooperative R&D between small businesses and non-profit research institutions. It supports early-stage research and development with commercial potential in health-related fields, encouraging participation from women-owned and socially and economically disadvantaged businesses. NIH has standard application due dates.

Small Business Technology Transfer Grant, Parent STTR R41/R42, Clinical Trial Optional (PA-27-102) is sponsored by National Institutes of Health (NIH). This NIH Small Business Technology Transfer (STTR) Grant supports U.S. small businesses conducting biomedical or life-sciences research and development in partnership with nonprofit research institutions. It is part of the federal STTR program, aimed at helping small companies develop technologies and products that improve health, extend life, and reduce illness and disability.

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This funding opportunity invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications.

Parent Small Business Technology Transfer (STTR) (R41/R42 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). The NIH STTR program supports early-stage research and development projects for U. S. small businesses, requiring formal collaboration with a research institution. It aims to advance innovative biomedical technologies towards public health impact.

Small Business Program at NINR is sponsored by National Institute of Nursing Research (NINR) / NIH. The Small Business Program at NINR provides technical and financial support for small businesses to develop new and innovative products, technologies, and services that improve health. This can include technologies for managing chronic conditions, which aligns with lymphedema and chronic venous insufficiency.

NIA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Funding is sponsored by National Institute on Aging (NIA) (NIH). The NIA Small Business Programs offer early-stage funding to small businesses and researchers developing innovative treatments or technologies to promote healthier aging, including a broad range of research topics and targeted solicitations for Alzheimer's disease and related de…

Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health (NOT-EB-23-005) is sponsored by National Institutes of Health (NIH). This Notice of Special Interest (NOSI) supports small business initiatives focused on innovative tools and technologies to improve outcomes for maternal health.

Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health (NOT-EB-21-001) is sponsored by National Institutes of Health (NIH). This funding opportunity invites Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality. It is part of the IMPROVE initiative, supporting research to reduce preventable maternal deaths and improve women's health during and after pregnancy.

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This NIH funding opportunity supports research projects. While not directly focused on classical liberalism, universities conducting social science or behavioral research with a broad interpretation of 'translational research' may find this relevant.

SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). Operating under the NIH SBIR/STTR Solicitation 2026, the Commercialization Readiness Pilot program provides funding for high-value technical assistance and late-stage product development activities for small businesses that have completed a Phase II SBIR or STTR project.

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI) and other participating NIH Institutes. This Notice of Funding Opportunity (NOFO) encourages applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes.

Notice of Special Interest (NOSI): Interventions to promote mental well-being in populations that experience health disparities through social, cultural, and environmental connectedness is sponsored by National Institutes of Health (NIH) Office of Disease Prevention. This Notice of Special Interest (NOSI) encourages research on interventions that promote mental well-being in populations experiencing health disparities. It emphasizes the role of social, cultural, and environmental connectedness.

PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) is sponsored by National Library of Medicine (NLM), National Institutes of Health (NIH). This solicitation supports cooperative research and development projects between small business concerns and research institutions in biomedical informatics and data science.

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA) - NIH. This program supports research into novel mechanisms underlying neuropsychiatric symptoms in Alzheimer's dementia, which can be highly relevant to understanding and treating delirium in this population.

NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Funding Opportunities (Omnibus Solicitation) is sponsored by National Institutes of Health (NIH). The NIH SBIR and STTR programs provide funding to small businesses to engage in research and development activities with strong potential for commercialization in health-related technologies.

Interventions to promote mental well-being in populations that experience health disparities through social, cultural, and environmental connectedness (NOT-OD-23-194) is sponsored by NIH Office of Disease Prevention. This Notice of Special Interest (NOSI) encourages research on interventions to promote mental well-being in populations that experience health disparities by leveraging social, cultural, and environmental connectedness.

Parent Small Business Innovation Research (SBIR) / Parent Small Business Technology Transfer (STTR) is sponsored by National Institutes of Health (NIH). These programs provide funding for U. S. small businesses developing innovative biomedical technologies. New policy changes allow Technical and Business Assistance (TABA) funds to be used to strengthen cybersecurity and screen for foreign risk.

Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets is sponsored by National Institutes of Health (NIH), National Institute of Mental Health (NIMH). This NOSI highlights interest in implementation research grant applications designed in partnership with domestic and global service providers to advance HIV prevention and treatment goals and targets.

PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Library of Medicine (NLM), National Institutes of Health (NIH). This omnibus solicitation supports small businesses engaging in research and development in biomedical informatics and data science, leading to commercialization.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (NCI) is sponsored by National Cancer Institute (NCI) - NIH. The NCI SBIR and STTR programs support small businesses in developing innovative cancer technologies with strong potential to improve health outcomes. This includes therapeutics, diagnostics, imaging technologies, and tools for cancer biology research.

High-Risk, High-Reward Research (HRHR) Program - NIH Director's Pioneer Award (DP1) is sponsored by NIH Common Fund. The NIH Director's Pioneer Award (DP1) supports individual scientists of exceptional creativity who propose bold approaches to address major challenges in biomedical and behavioral research. This program complements traditional grant programs by supporting highly innovative research with broad potential impacts.

NIH Director's Pioneer Award Program (DP1 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) Common Fund. This program supports individual scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformativ…

NIH Director's Early Independence Award (DP5 Clinical Trial Optional) is sponsored by NIH Common Fund, Office of Strategic Coordination. Part of the High-Risk, High-Reward Research program, this award supports promising, newly graduated scientists with the intellect, scientific creativity, drive, and maturity to bypass the traditional postdoctoral training period and launch independent research careers.

NIH Director's Early Independence Award (DP5 Clinical Trial Optional) is sponsored by NIH Common Fund. The NIH Director's Early Independence Award supports exceptional junior scientists who have recently received their doctoral degree or completed their medical residency and wish to bypass the traditional postdoctoral training period to launch directly into an independent researc…

Computational Approaches to Curation at Scale for Biomedical Research Assets (R01) is sponsored by National Library of Medicine (NLM), NIH. This grant supports research on computational approaches to curating biomedical research assets at scale. The focus is on improving the efficiency and effectiveness of data curation for large and complex biomedical datasets.

NIHR James Lind Alliance Priority Setting Partnerships rolling funding opportunity (HSDR Programme) is sponsored by National Institute for Health and Care Research (NIHR) - Health and Social Care Delivery Research (HSDR) Programme. This opportunity invites applications that address research priorities identified by James Lind Alliance (JLA) Priority Setting Partnerships (PSP). The HSDR Programme funds research to improve health and social care services.

NIHR Biomedical Research Centres (BRCs) is sponsored by National Institute for Health and Care Research (NIHR). A new open funding opportunity competition for early phase translational research infrastructure. These centres undertake world-leading research into mechanistic biomedical drivers and develop targeted interventions to prevent and treat disease and its health consequences.

Practice-Based Research on Youth Suicide Prevention Pilot Program is sponsored by National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH) - Center for Accelerating Suicide Prevention in Real-World Settings (ASPIRES). This pilot program funds small-scale, innovative, or exploratory clinical research focused on youth suicide prevention in practice settings.

NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) is sponsored by National Cancer Institute (NCI) / National Institutes of Health (NIH). This NOFO is part of the NCI Community Oncology Research Program (NCORP), designed to enhance generalizability and dissemination of clinical trial and human subject research study results through accrual in various community settings.